AVEO Pharmaceuticals Inc (AVEO) Stock
AVEO is no longer traded. AVEO Pharmaceuticals was delisted from the Nasdaq in January 2023.
Prices on this page are historical; the last trade was January 18, 2023 at $15.00.
AVEO Pharmaceuticals stock price history
AVEO final trading statistics
- Final close
- $15.00
- Final trading day
- Jan 18, 2023
- Market cap at delisting
- $521.45M
- Shares outstanding
- 34.76M
- Final 52-week range
- $3.06 – $15.00
- Avg. volume (final 3 mo.)
- 863,804
- All-time high (split-adj.)
- $207.70 · Jul 2011
- All-time low (split-adj.)
- $2.60 · Mar 2020
- Return since IPO
- -83.3%
- Beta
- 0.98
- Book value / share
- $0.83
- Price / book
- 18.01
AVEO Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $38.87M | -$53.3M | -$1.72 |
| FY2020 | $6.02M | -$35.6M | -$1.71 |
| FY2019 | $28.80M | $9.4M | $0.62 |
| FY2018 | $5.41M | -$5.3M | -$0.50 |
| FY2017 | $7.58M | -$65.0M | -$0.34 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About AVEO Pharmaceuticals Inc
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
AVEO Pharmaceuticals stock FAQ
What happened to AVEO Pharmaceuticals stock?
AVEO Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $15.00 on January 18, 2023.
Is AVEO stock still trading?
No. AVEO was delisted from the Nasdaq in January 2023 and no longer trades on a U.S. exchange.
What was the last price of AVEO stock?
AVEO closed at $15.00 on its final trading day, January 18, 2023, for a market value of about $521.45M.
What were AVEO Pharmaceuticals's revenue and earnings in its last full fiscal year?
AVEO Pharmaceuticals reported revenue of $38.87M and net income of -$53.3M in fiscal 2021, its last full year as a public company.
When did AVEO Pharmaceuticals go public?
AVEO Pharmaceuticals Inc stock began trading on March 12, 2010.